BioSpace News Archive

NEUWAY Pharma GmbH announced two new appointments in its senior leadership team: Dr Oliver Ernst, formerly NEUWAY’s Chief Operating Officer, was promoted to Chief Executive Officer, and Dr Thomas Christoph was appointed as new Chief Development Officer.

Decibel Therapeutics announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable restoration of hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.

Skye Bioscience, Inc. has been advised by its contract manufacturer (“CMO”) that it has completed the production of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) for Skye’s Phase 1 clinical trial.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination committees, has resigned as a director of the Company for personal reasons effective immediately.

Alnylam Receives Approval in Europe for AMVUTTRA ® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy.

Scholar Rock today announced that its Board of Directors appointed Jay Backstrom, M.D., M.P.H., as Chief Executive Officer-Elect, effective September 20, 2022.

Synairgen plc today announces it will present its positive findings from the analysis of data from 60 and 90-day follow-up visits from the Phase 3 SPRINTER trial in patients hospitalised with COVID-19 at IDWeek 2022 to be held 19-23 October 2022 in Washington, D.C.

CHADD is proud to announce the appointment of Laurie Kulikosky, CAE, as the organization’s new Chief Executive Officer, effective October 17, 2022.

ImmuneSensor Therapeutics Inc. announced the Company has been awarded a $16.1 million Product Development Research Grant from the Cancer Prevention and Research Institute of Texas to advance Phase 2 studies evaluating IMSA101, a STING agonist, in combination with immune checkpoint inhibitors and radiotherapy for the treatment of metastatic solid tumor malignancies.

Evotec SE announced that the U.S. Department of Defense has awarded Evotec’s Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody -based drug product prototypes targeting plague.